Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response. | J Exp Clin Cancer Res | 2023 | 37898752 | PubTator, text mining | PubMed |
| Flaviviruses in AntiTumor Therapy. | Viruses | 2023 | 37896752 | PubTator, text mining | PubMed |
| The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook. | Pharmaceuticals (Basel) | 2023 | 37895882 | PubTator, text mining | PubMed |
| Identification of Molecular Subtypes and Prognostic Characteristics of Adrenocortical Carcinoma Based on Unsupervised Clustering. | Int J Mol Sci | 2023 | 37895143 | PubTator, text mining | PubMed |
| Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers. | Int J Mol Sci | 2023 | 37895012 | PubTator, text mining | PubMed |
| Erythroid Cells as Full Participants in the Tumor Microenvironment. | Int J Mol Sci | 2023 | 37894821 | PubTator, text mining | PubMed |
| Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment. | Biomedicines | 2023 | 37892995 | PubTator, text mining | PubMed |
| CEP55 as a Promising Immune Intervention Marker to Regulate Tumor Progression: A Pan-Cancer Analysis with Experimental Verification. | Cells | 2023 | 37887301 | PubTator, text mining | PubMed |
| The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment. | Front Immunol | 2023 | 37881432 | PubTator, text mining | PubMed |
| Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer. | BMC Med Genomics | 2023 | 37880682 | PubTator, text mining | PubMed |
| Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. | J Cancer Res Clin Oncol | 2023 | 37874352 | PubTator, text mining | PubMed |
| The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer. | Nat Commun | 2023 | 37872170 | PubTator, text mining | PubMed |
| Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort. | Pathology | 2023 | 37863710 | PubTator, text mining | PubMed |
| Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer. | Front Oncol | 2023 | 37860188 | PubTator, text mining | PubMed |
| PSGL-1: a novel immune checkpoint driving T-cell dysfunction in obstructive sleep apnea. | Front Immunol | 2023 | 37854605 | PubTator, text mining | PubMed |
| Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant. | Cancer Immunol Res | 2023 | 37847894 | PubTator, text mining | PubMed |
| [Research Progress of Immune Heterogeneity in Leukemia Microenvironment--Review]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2023 | 37846718 | PubTator, text mining | PubMed |
| Taxifolin Inhibits the Growth of Non-Small-Cell Lung Cancer via Downregulating Genes Displaying Novel and Robust Associations with Immune Evasion Factors. | Cancers (Basel) | 2023 | 37835514 | PubTator, text mining | PubMed |
| Radiation Therapy for Gestational Trophoblastic Neoplasia: Forward-Looking Lessons Learnt. | Cancers (Basel) | 2023 | 37835511 | PubTator, text mining | PubMed |
| Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies. | Cancers (Basel) | 2023 | 37835491 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=20